Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paula Ellenberg

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Molecules (Basel, Switzerland)|April 13, 2023
Targeting HIV-1 Reverse Transcriptase Using a Fragment-Based ApproachMahta Mansouri, Shawn Rumrill, Shane Dawson, et al.
Journal of the International AIDS Society|July 2, 2025
The science at HIVR4P 2024: The era of choice in biomedical HIV preventionBeatriz Grinsztejn, Victor Appay, Linda-Gail Bekker, et al.
Molecular Therapy. Methods & Clinical Development|December 17, 2024
mRNA vaccines encoding membrane-anchored RBDs of SARS-CoV-2 mutants induce strong humoral responses and can overcome immune imprintingHareth A Al-Wassiti, Stewart A Fabb, Samantha L Grimley, et al.
The Lancet. Infectious Diseases|April 22, 2021
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trialKeith J Chappell, Francesca L Mordant, Zheyi Li, et al.
Ebiomedicine|December 6, 2021
A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2Thomas S Fulford, Huy Van, Nicholas A Gherardin, et al.
Ebiomedicine|May 6, 2023
Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccineGeorgia Deliyannis, Nicholas A Gherardin, Chinn Yi Wong, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Molecules (Basel, Switzerland)|April 13, 2023
Targeting HIV-1 Reverse Transcriptase Using a Fragment-Based ApproachMahta Mansouri, Shawn Rumrill, Shane Dawson, et al.
Journal of the International AIDS Society|July 2, 2025
The science at HIVR4P 2024: The era of choice in biomedical HIV preventionBeatriz Grinsztejn, Victor Appay, Linda-Gail Bekker, et al.
Molecular Therapy. Methods & Clinical Development|December 17, 2024
mRNA vaccines encoding membrane-anchored RBDs of SARS-CoV-2 mutants induce strong humoral responses and can overcome immune imprintingHareth A Al-Wassiti, Stewart A Fabb, Samantha L Grimley, et al.
The Lancet. Infectious Diseases|April 22, 2021
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trialKeith J Chappell, Francesca L Mordant, Zheyi Li, et al.
Ebiomedicine|December 6, 2021
A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2Thomas S Fulford, Huy Van, Nicholas A Gherardin, et al.
Ebiomedicine|May 6, 2023
Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccineGeorgia Deliyannis, Nicholas A Gherardin, Chinn Yi Wong, et al.
Pageof 2